Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 6/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | DDX3X | O00571 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18966935 | 0.82 | CYP19A1 (0.38) | DYRK1AHDAC1HDAC6ABCB1ABCG2 | |
| SCHEMBL24792887 | 0.80 | EPHX2 (0.42) | NOS3NOS1NOS2ESR1ESR2 | |
| SCHEMBL1198225 | 0.80 | DYRK1A (0.36) | DYRK1AHDAC1HDAC6ABCB1ABCG2 | |
| SCHEMBL13171693 | 0.79 | DYRK1A (0.38) | NOS3NOS1NOS2DYRK1AHDAC1 | |
| SCHEMBL16805453 | 0.77 | NOS3 (0.35) | NOS3NOS1NOS2HDAC1ESR1 | |
| SCHEMBL23542447 | 0.77 | KCNH2 (0.36) | NOS3NOS1NOS2HDAC1ESR1 | |
| SCHEMBL1064984 | 0.77 | DYRK1A (0.39) | DYRK1AHDAC1HDAC6ABCB1ABCG2 | |
| SCHEMBL9974274 | 0.77 | DYRK1A (0.39) | DYRK1AHDAC1HDAC6ABCB1ABCG2 | |
| SCHEMBL23847781 | 0.77 | MEN1 (0.34) | DYRK1AHDAC1HDAC6 | |
| SCHEMBL20762092 | 0.75 | DYRK1A (0.38) | DYRK1AHDAC1HDAC6ABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | NOS3 4664/4885NOS1 4611/4885NOS2 4722/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | NOS3 4629/4885NOS1 4551/4885NOS2 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.